Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas P Restifo

Showing results (251-260 of 260) with videos related to

Pageof 26
Sort By:
You have reached the last page of results.This site can display upto 260 results.
Nature Medicine|January 30, 2021
Author Correction: Multimodel preclinical platform predicts clinical response of melanoma to immunotherapyEva Pérez-Guijarro, Howard H Yang, Romina E Araya, et al.
The Journal of Clinical Investigation|December 15, 2015
Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapyChristopher A Klebanoff, Christopher D Scott, Anthony J Leonardi, et al.
Signal Transduction and Targeted Therapy|August 8, 2024
LIM-domain-only 4 (LMO4) enhances CD8<sup>+</sup> T-cell stemness and tumor rejection by boosting IL-21-STAT3 signalingRoland C Schelker, Jessica Fioravanti, Fabio Mastrogiovanni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2016
Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic MelanomaStephanie L Goff, Mark E Dudley, Deborah E Citrin, et al.
Blood|May 20, 2009
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigenLaura A Johnson, Richard A Morgan, Mark E Dudley, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 5, 2013
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapyRichard A Morgan, Nachimuthu Chinnasamy, Daniel Abate-Daga, et al.
Nature Immunology|May 23, 2017
BACH2 immunodeficiency illustrates an association between super-enhancers and haploinsufficiencyBehdad Afzali, Juha Grönholm, Jana Vandrovcova, et al.
Med (New York, N.Y.)|August 25, 2022
Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockadeDouglas C Palmer, Beau R Webber, Yogin Patel, et al.
Oncoimmunology|July 3, 2015
Consensus nomenclature for CD8<sup>+</sup> T cell phenotypes in cancerLionel Apetoh, Mark J Smyth, Charles G Drake, et al.
Oncotarget|December 25, 2014
Classification of current anticancer immunotherapiesLorenzo Galluzzi, Erika Vacchelli, José-Manuel Bravo-San Pedro, et al.
Pageof 26

Showing results (251-260 of 260) with videos related to

Sort By:
Pageof 26
You have reached the last page of results.This site can display upto 260 results.
Nature Medicine|January 30, 2021
Author Correction: Multimodel preclinical platform predicts clinical response of melanoma to immunotherapyEva Pérez-Guijarro, Howard H Yang, Romina E Araya, et al.
The Journal of Clinical Investigation|December 15, 2015
Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapyChristopher A Klebanoff, Christopher D Scott, Anthony J Leonardi, et al.
Signal Transduction and Targeted Therapy|August 8, 2024
LIM-domain-only 4 (LMO4) enhances CD8<sup>+</sup> T-cell stemness and tumor rejection by boosting IL-21-STAT3 signalingRoland C Schelker, Jessica Fioravanti, Fabio Mastrogiovanni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2016
Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic MelanomaStephanie L Goff, Mark E Dudley, Deborah E Citrin, et al.
Blood|May 20, 2009
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigenLaura A Johnson, Richard A Morgan, Mark E Dudley, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 5, 2013
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapyRichard A Morgan, Nachimuthu Chinnasamy, Daniel Abate-Daga, et al.
Nature Immunology|May 23, 2017
BACH2 immunodeficiency illustrates an association between super-enhancers and haploinsufficiencyBehdad Afzali, Juha Grönholm, Jana Vandrovcova, et al.
Med (New York, N.Y.)|August 25, 2022
Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockadeDouglas C Palmer, Beau R Webber, Yogin Patel, et al.
Oncoimmunology|July 3, 2015
Consensus nomenclature for CD8<sup>+</sup> T cell phenotypes in cancerLionel Apetoh, Mark J Smyth, Charles G Drake, et al.
Oncotarget|December 25, 2014
Classification of current anticancer immunotherapiesLorenzo Galluzzi, Erika Vacchelli, José-Manuel Bravo-San Pedro, et al.
Pageof 26